Literature DB >> 21937078

The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Charles C Guo1, Yan Wang, Li Xiao, Patricia Troncoso, Bogdan A Czerniak.   

Abstract

Recent studies have revealed the presence of TMPRSS2-ERG gene fusion in both primary and metastatic prostate cancers. However, the relationship between primary and corresponding metastatic prostate cancers with respect to the status of this gene fusion remains unclear. Using fluorescence in situ hybridization, we evaluated the rearrangement of the ERG gene in the radical prostatectomy specimens and corresponding lymph node metastases from 19 patients with prostate cancer. The mean age of the patients was 61 years, and the median Gleason score in the radical prostatectomy specimens was 7 (4 + 3). Prostate cancer was unifocal in 6 cases and multifocal in 13 cases, including 10 with 2 foci and 3 with 3 foci. In the primary prostate cancers, rearrangement of the ERG gene was observed in 13 cases and associated with deletion of the 5' ERG gene in 8 cases. In the metastases, the ERG rearrangement was present in 10 cases and associated with deletion of the 5' ERG gene in 6 cases. In unifocal prostate cancers, the status of the ERG rearrangement was concordant between the primary prostate cancer and metastasis in 5 of 6 cases. In multifocal prostate cancer, despite a significant interfocal discordance, the status of the ERG rearrangement was concordant between the index (largest) primary tumor focus and metastasis in all 13 cases. Our study demonstrates a close relationship of the TMPRSS2-ERG gene fusion status between primary and metastatic prostate cancer. The concordance of the ERG gene rearrangement status between the index primary tumor focus and metastasis suggests that metastasis most likely arises from the index tumor focus in multifocal prostate cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937078      PMCID: PMC3880196          DOI: 10.1016/j.humpath.2011.06.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  27 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

Review 2.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

3.  Evidence of independent origin of multiple tumors from patients with prostate cancer.

Authors:  L Cheng; S Y Song; T G Pretlow; F W Abdul-Karim; H J Kung; D V Dawson; W S Park; Y W Moon; M L Tsai; W M Linehan; M R Emmert-Buck; L A Liotta; Z Zhuang
Journal:  J Natl Cancer Inst       Date:  1998-02-04       Impact factor: 13.506

Review 4.  International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume.

Authors:  Theo H van der Kwast; Mahul B Amin; Athanase Billis; Jonathan I Epstein; David Griffiths; Peter A Humphrey; Rodolfo Montironi; Thomas M Wheeler; John R Srigley; Lars Egevad; Brett Delahunt
Journal:  Mod Pathol       Date:  2010-09-03       Impact factor: 7.842

5.  Detailed mapping of prostate carcinoma foci: biopsy strategy implications.

Authors:  M E Chen; D A Johnston; K Tang; R J Babaian; P Troncoso
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

6.  A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis.

Authors:  Jacques Lapointe; Young H Kim; Melinda A Miller; Chunde Li; Gulsah Kaygusuz; Matt van de Rijn; David G Huntsman; James D Brooks; Jonathan R Pollack
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

7.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.

Authors:  Rohit Mehra; Scott A Tomlins; Ronglai Shen; Owais Nadeem; Lei Wang; John T Wei; Kenneth J Pienta; Debashis Ghosh; Mark A Rubin; Arul M Chinnaiyan; Rajal B Shah
Journal:  Mod Pathol       Date:  2007-03-02       Impact factor: 7.842

8.  Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2.

Authors:  B Lin; C Ferguson; J T White; S Wang; R Vessella; L D True; L Hood; P S Nelson
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

9.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

10.  Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.

Authors:  J Clark; S Merson; S Jhavar; P Flohr; S Edwards; C S Foster; R Eeles; F L Martin; D H Phillips; M Crundwell; T Christmas; A Thompson; C Fisher; G Kovacs; C S Cooper
Journal:  Oncogene       Date:  2006-10-16       Impact factor: 9.867

View more
  12 in total

Review 1.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

Review 2.  Prognostic prostate tissue biomarkers of potential clinical use.

Authors:  Theodorus H Van der Kwast
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

3.  Prostatic adenocarcinoma CNS parenchymal and dural metastases: alterations in ERG, CHD1 and MAP3K7 expression.

Authors:  D Ryan Ormond; B K Kleinschmidt-DeMasters; Daniel Cavalcante; Elizabeth E Smith; Scott D Cramer; M Scott Lucia
Journal:  J Neurooncol       Date:  2019-01-17       Impact factor: 4.130

Review 4.  Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Authors:  M J Connor; M A Gorin; H U Ahmed; R Nigam
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-12       Impact factor: 5.554

Review 5.  [Focal prostate cancer therapy: capabilities, limitations and prospects].

Authors:  D Baumunk; A Blana; R Ganzer; T Henkel; J Köllermann; A Roosen; S Machtens; G Salomon; L Sentker; U Witzsch; K U Köhrmann; M Schostak
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

6.  TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.

Authors:  Rachel Deplus; Carine Delliaux; Nathalie Marchand; Anne Flourens; Nathalie Vanpouille; Xavier Leroy; Yvan de Launoit; Martine Duterque-Coquillaud
Journal:  Oncotarget       Date:  2017-02-14

7.  Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer.

Authors:  Manuela Krumbholz; Abbas Agaimy; Robert Stoehr; Maximilian Burger; Sven Wach; Helge Taubert; Bernd Wullich; Arndt Hartmann; Markus Metzler
Journal:  Dis Markers       Date:  2019-12-12       Impact factor: 3.434

Review 8.  Blood-Derived Biomarkers of Diagnosis, Prognosis and Therapy Response in Prostate Cancer Patients.

Authors:  Katalin Balázs; Lilla Antal; Géza Sáfrány; Katalin Lumniczky
Journal:  J Pers Med       Date:  2021-04-13

Review 9.  Focal therapy for prostate cancer: rationale and treatment opportunities.

Authors:  V Kasivisvanathan; M Emberton; H U Ahmed
Journal:  Clin Oncol (R Coll Radiol)       Date:  2013-06-04       Impact factor: 4.126

10.  High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases.

Authors:  Franziska Brandi; Katharina Grupp; Claudia Hube-Magg; Martina Kluth; Dagmar Lang; Sarah Minner; Christina Möller-Koop; Markus Graefen; Hans Heinzer; Maria Christina Tsourlakis; Corinna Wittmer; Frank Jacobsen; Hartwig Huland; Stefan Steurer; Patrick Lebok; Andrea Hinsch; Waldemar Wilczak; Thorsten Schlomm; Ronald Simon
Journal:  Oncol Lett       Date:  2018-09-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.